The current PE ratio for Biogen stock as of Feb 21, 2025 is 12.55. This is calculated based on the current EPS of $11.21 and the stock price of $140.64 per share. The P/E ratio has a decrease of 42% from the past four quarters average of 21.7.
The average historical PE ratio of Biogen for the last ten years is 17.97. The current PE ratio of 12.55 is 30% below the historical average. Over the past ten years, BIIB's PE ratio was at its highest in the Dec 2023 quarter at 32.27, when the stock price was $258.77 and the EPS was $8.02. The lowest value was in the Jun 2020 quarter, when it reached 7.83 with a price of $267.55 and an EPS of $34.19.
Maximum annual increase: 144.28% in 2023
Maximum annual decrease: -57.73% in 2024
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 13.64 | -57.73% | $152.92 | $11.21 |
2023 | 32.27 | 144.28% | $258.77 | $8.02 |
2022 | 13.21 | -42.52% | $276.92 | $20.96 |
2021 | 22.98 | 133.3% | $239.92 | $10.44 |
2020 | 9.85 | 4.45% | $244.86 | $24.86 |
2019 | 9.43 | -32.21% | $296.73 | $31.47 |
2018 | 13.91 | -47.86% | $300.92 | $21.63 |
2017 | 26.68 | 59.57% | $318.57 | $11.94 |
2016 | 16.72 | -16.06% | $283.58 | $16.96 |
2015 | 19.92 | -27.11% | $306.35 | $15.38 |
2014 | 27.33 | -23.17% | $339.45 | $12.42 |
2013 | 35.57 | 40.93% | $279.57 | $7.86 |
2012 | 25.24 | 16.74% | $146.37 | $5.8 |
2011 | 21.62 | 28.31% | $110.05 | $5.09 |
2010 | 16.85 | 6.11% | $67.05 | $3.98 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 13.64 | -21.83% | $152.92 | $11.21 |
Sep 2024 | 17.45 | -40.01% | $193.84 | $11.11 |
Jun 2024 | 29.09 | 8.59% | $231.82 | $7.97 |
Mar 2024 | 26.79 | -16.98% | $215.63 | $8.05 |
Dec 2023 | 32.27 | 27.45% | $258.77 | $8.02 |
Sep 2023 | 25.32 | 64.31% | $257.01 | $10.15 |
Jun 2023 | 15.41 | 19.92% | $284.85 | $18.48 |
Mar 2023 | 12.85 | -2.73% | $278.03 | $21.64 |
Dec 2022 | 13.21 | -2.65% | $276.92 | $20.96 |
Sep 2022 | 13.57 | -6.61% | $267 | $19.68 |
Jun 2022 | 14.53 | -32.45% | $203.94 | $14.04 |
Mar 2022 | 21.51 | -6.4% | $210.6 | $9.79 |
Dec 2021 | 22.98 | -14.83% | $239.92 | $10.44 |
Sep 2021 | 26.98 | -0.74% | $282.99 | $10.49 |
Jun 2021 | 27.18 | 87.97% | $346.27 | $12.74 |
BIIB's current P/E ratio is below the 3, 5 and 10-year averages.
Compared to its peer stocks JNJ and ABBV, BIIB's PE ratio stands lower. Biogen's PE ratio is trading below the peer group average of 46.59.
Stock name | PE ratio | Market cap |
---|---|---|
BIIB Biogen Inc | 12.55 | $20.59B |
JNJ Johnson & Johnson | 27.79 | $390.76B |
PFE Pfizer Inc | 34.61 | $149.04B |
AMGN Amgen Inc | 39.77 | $162.78B |
ABBV AbbVie Inc | 84.2 | $356.74B |
QGEN Qiagen NV | 106.95 | $8.86B |
GILD Gilead Sciences Inc | 1,099.5 | $137.03B |
BIO Bio-Rad Laboratories Inc | N/A | $7.85B |
ILMN Illumina Inc | N/A | $14.92B |
SGMO Sangamo Therapeutics Inc | N/A | $223.25M |
The price to earnings ratio for BIIB stock as of Feb 21, 2025, stands at 12.55.
As an average over the last 3 years, BIIB stock has a PE ratio of 19.64.
As an average over the last 5 years, BIIB stock has a PE ratio of 18.2.
The highest quarterly PE ratio in the last ten years has been 32.27 and it was in the Dec 2023 quarter.
The current price to earnings ratio of BIIB is 30% lower than the 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Feb 21, 2025), Biogen's stock price is $140.64. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $11.21. Therefore, Biogen's P/E ratio for today is 12.55. PE RATIO(12.55) = STOCK PRICE($140.64) / TTM EPS($11.21)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.